Data on the oral CRTh2 antagonist QAW039 (fevipiprant) in patients with uncontrolled allergic asthma
This article contains data on clinical endpoints (Peak Flow Expiratory Rate, fractional exhaled nitric oxide and total IgE serum levels) and plasma pharmacokinetic parameters concerning the use of the oral CRTh2 antagonist QAW039 (fevipiprant) in mild to moderate asthma patients. Information on expe...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2016-12-01
|
| Series: | Data in Brief |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2352340916305406 |
| _version_ | 1828969091753312256 |
|---|---|
| author | Veit J. Erpenbeck Todor A. Popov David Miller Steven F. Weinstein Sheldon Spector Baldur Magnusson Wande Osuntokun Paul Goldsmith Markus Weiss Jutta Beier |
| author_facet | Veit J. Erpenbeck Todor A. Popov David Miller Steven F. Weinstein Sheldon Spector Baldur Magnusson Wande Osuntokun Paul Goldsmith Markus Weiss Jutta Beier |
| author_sort | Veit J. Erpenbeck |
| collection | DOAJ |
| description | This article contains data on clinical endpoints (Peak Flow Expiratory Rate, fractional exhaled nitric oxide and total IgE serum levels) and plasma pharmacokinetic parameters concerning the use of the oral CRTh2 antagonist QAW039 (fevipiprant) in mild to moderate asthma patients. Information on experimental design and methods on how this data was obtained is also described. Further interpretation and discussion of this data can be found in the article “The oral CRTh2 antagonist QAW039 (fevipiprant): a phase II study in uncontrolled allergic asthma” (Erpenbeck et al., in press) [1]. |
| first_indexed | 2024-12-14T12:24:59Z |
| format | Article |
| id | doaj.art-1fbdbd306fae4599b5b54cee145b776c |
| institution | Directory Open Access Journal |
| issn | 2352-3409 |
| language | English |
| last_indexed | 2024-12-14T12:24:59Z |
| publishDate | 2016-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Data in Brief |
| spelling | doaj.art-1fbdbd306fae4599b5b54cee145b776c2022-12-21T23:01:21ZengElsevierData in Brief2352-34092016-12-019C19920510.1016/j.dib.2016.08.039Data on the oral CRTh2 antagonist QAW039 (fevipiprant) in patients with uncontrolled allergic asthmaVeit J. Erpenbeck0Todor A. Popov1David Miller2Steven F. Weinstein3Sheldon Spector4Baldur Magnusson5Wande Osuntokun6Paul Goldsmith7Markus Weiss8Jutta Beier9Novartis Pharma AG, Basel, SwitzerlandClinic of Allergy & Asthma, Medical University Sofia, Sofia, BulgariaNEMRA, North Dartmouth, MA, United StatesAllergy & Immunology, Allergy and Asthma Specialists Medical Group and Research Center, CA, United StatesAllergy & Asthma, California Allergy and Asthma Medical Group Inc, CA, United StatesNovartis Pharma AG, Basel, SwitzerlandNovartis Pharmaceuticals, Horsham, United KingdomNovartis Pharmaceuticals, Horsham, United KingdomNovartis Pharma AG, Basel, SwitzerlandINSAF, Respiratory Research Institute GmbH, Wiesbaden, GermanyThis article contains data on clinical endpoints (Peak Flow Expiratory Rate, fractional exhaled nitric oxide and total IgE serum levels) and plasma pharmacokinetic parameters concerning the use of the oral CRTh2 antagonist QAW039 (fevipiprant) in mild to moderate asthma patients. Information on experimental design and methods on how this data was obtained is also described. Further interpretation and discussion of this data can be found in the article “The oral CRTh2 antagonist QAW039 (fevipiprant): a phase II study in uncontrolled allergic asthma” (Erpenbeck et al., in press) [1].http://www.sciencedirect.com/science/article/pii/S2352340916305406 |
| spellingShingle | Veit J. Erpenbeck Todor A. Popov David Miller Steven F. Weinstein Sheldon Spector Baldur Magnusson Wande Osuntokun Paul Goldsmith Markus Weiss Jutta Beier Data on the oral CRTh2 antagonist QAW039 (fevipiprant) in patients with uncontrolled allergic asthma Data in Brief |
| title | Data on the oral CRTh2 antagonist QAW039 (fevipiprant) in patients with uncontrolled allergic asthma |
| title_full | Data on the oral CRTh2 antagonist QAW039 (fevipiprant) in patients with uncontrolled allergic asthma |
| title_fullStr | Data on the oral CRTh2 antagonist QAW039 (fevipiprant) in patients with uncontrolled allergic asthma |
| title_full_unstemmed | Data on the oral CRTh2 antagonist QAW039 (fevipiprant) in patients with uncontrolled allergic asthma |
| title_short | Data on the oral CRTh2 antagonist QAW039 (fevipiprant) in patients with uncontrolled allergic asthma |
| title_sort | data on the oral crth2 antagonist qaw039 fevipiprant in patients with uncontrolled allergic asthma |
| url | http://www.sciencedirect.com/science/article/pii/S2352340916305406 |
| work_keys_str_mv | AT veitjerpenbeck dataontheoralcrth2antagonistqaw039fevipiprantinpatientswithuncontrolledallergicasthma AT todorapopov dataontheoralcrth2antagonistqaw039fevipiprantinpatientswithuncontrolledallergicasthma AT davidmiller dataontheoralcrth2antagonistqaw039fevipiprantinpatientswithuncontrolledallergicasthma AT stevenfweinstein dataontheoralcrth2antagonistqaw039fevipiprantinpatientswithuncontrolledallergicasthma AT sheldonspector dataontheoralcrth2antagonistqaw039fevipiprantinpatientswithuncontrolledallergicasthma AT baldurmagnusson dataontheoralcrth2antagonistqaw039fevipiprantinpatientswithuncontrolledallergicasthma AT wandeosuntokun dataontheoralcrth2antagonistqaw039fevipiprantinpatientswithuncontrolledallergicasthma AT paulgoldsmith dataontheoralcrth2antagonistqaw039fevipiprantinpatientswithuncontrolledallergicasthma AT markusweiss dataontheoralcrth2antagonistqaw039fevipiprantinpatientswithuncontrolledallergicasthma AT juttabeier dataontheoralcrth2antagonistqaw039fevipiprantinpatientswithuncontrolledallergicasthma |